ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
Current Treatment Patterns and Outcomes of Sex Cord Stromal Tumor Patients in Japan.
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSex cord-stromal tumors (SCSTs) constitute approximately 5% of testicular malignancies. This investigation aimed to elucidate contemporary therapeutic approaches and clinical outcomes for patients with testicular SCSTs in Japan.
methodsParticipating institutions included Japan Clinical Oncology Group facilities, affiliated centers, and institutions with published cases. Clinical data and histopathological findings were compiled. Central pathological review involved representative tissue sections when available. Kaplan-Meier methodology assessed recurrence-free survival (RFS) and overall survival (OS). Stage I patients were stratified by cumulative pathological risk factors (tumor diameter ≥ 5 cm, necrosis, moderate to severe nuclear atypia, lymphovascular invasion, infiltrative growth, and ≥ 3 mitoses per 10 high-power fields).
resultsAmong 116 patients from 66 institutions, 112 met inclusion criteria. Histological distribution included Leydig cell (n = 54), Sertoli cell (n = 36), and other variants (n = 22). Twelve patients presented with metastatic disease; ten received systemic chemotherapy, with 20.8% five-year OS. Among 91 stage I patients with follow-up data, eleven developed recurrence. Patients with > 2 risk factors demonstrated significantly inferior RFS compared with those showing ≤ 1 factor (26.4 versus 98.6% at 5 years, p < 0.0001). Surgical intervention predominated in the recurrent cases (81.8%, 9/11), while chemotherapy was administered to 45.5% (5/11), and selected patients achieved prolonged disease control through repeated surgical resection without systemic therapy. OS rates were 90.9% and 50.5% at 5 and 10 years.
conclusionsPatients with synchronous metastatic presentation demonstrated poor survival. Stage I patients with > 2 pathological risk factors showed reduced RFS, with surgical management potentially efficacious for recurrent disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.